therapeutics

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

March 20, 2026 16:30 ET  | Source: Zevra Therapeutics BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS:…

4 weeks ago

Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics

The Atlas will expand known evolutionary genetic diversity by 100x, collecting novel genomic data from over 100 million new species…

1 month ago

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

March 17, 2026 22:46 ET  | Source: CytomX Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) --…

1 month ago

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2026 17:33 ET  | Source: Tango Therapeutics Sub, Inc BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics,…

1 month ago

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

March 06, 2026 18:15 ET  | Source: Lisata Therapeutics, Inc. Each Lisata stockholder to receive $5.00 per share in cash…

1 month ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting…

2 months ago

Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing

Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”), a Delaware-incorporated, clinical-stage oncology biotechnology company, today announced…

2 months ago

Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit

LEHI, Utah, March 2, 2026 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies grounded in human biology, today…

2 months ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day…

2 months ago

Polaroid Therapeutics (PTx) Receives CE Mark for POLTX_Fiber: the first application of APT to launch a new standard in wound care

Introducing Antimicrobial Polymer Technology (APT™) in POLTX_Fiber™, a Class IIb advanced wound care dressing that does not contribute to antimicrobial…

2 months ago